Tallac Therapeutics
Signal active
Organization
Contact Information
Overview
Tallac Therapeutics offers next-generation immunotherapies for cancer patients.
The company is based in Burlingame, California.
About
Industries
Biotechnology, Health Care, Therapeutics
Founded
2018
Employees
11-50
Headquarters locations
Burlingame, California, United States, North America
Social
Profile Resume
Tallac Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $3.2B in funding across 36 round(s). With a team of 11-50 employees, Tallac Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Debt Financing - Tallac Therapeutics, raised $5.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
1
Lead Investors
0
Total Funding Amount
$88.2M
Details
1
Tallac Therapeutics has raised a total of $88.2M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Early Stage Venture | 62.0M |
Investors
Tallac Therapeutics is funded by 10 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Matrix Partners China | - | FUNDING ROUND - Matrix Partners China | 62.0M |
| Jerry Michaud | - | FUNDING ROUND - Jerry Michaud | 5.0M |
| Tallac Therapeutics | - | FUNDING ROUND - Tallac Therapeutics | 5.0M |
| Horizon Technology Finance | - | FUNDING ROUND - Horizon Technology Finance | 5.0M |
Recent Activity
News
Jun 23, 2024
PR Newswire - Clarivate Identifies Seven Innovators in Antibody Drug Conjugates in New Companies to Watch Report USA - English
News
Apr 10, 2024
Yahoo Finance - Tallac Therapeutics Presents New Preclinical Data on TAC-001 in Combination with Cancer Vaccines at the 2024 ...
News
Nov 15, 2023
Pharmaceutical Technology - Who are the leading innovators in gene silencing for the ...
News
Oct 23, 2023
ASCO Journals - Efficacy and Safety of Trastuzumab Deruxtecan in Patients ...
Funding Round
Aug 02, 2023
Tallac Therapeutics raised $5000000 on 2023-08-02 in Debt Financing
Funding Round
Dec 01, 2020
Tallac Therapeutics raised $62000000 on 2020-12-01 in Series A